Related Experiment Video

Updated: Sep 30, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Cardiovascular effects of prostaglandin F(2 alpha) and prostaglandin E(2) in Atlantic cod (Gadus morhua)

K-O Stensløkken1, L Sundin, G E Nilsson

  • 1Division of General Physiology, Department of Biology, University of Oslo, PO Box 1051, N-0316 Oslo, Norway. k.o.stenslokken@bio.uio.no

Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology
|July 18, 2002
PubMed

Insights

Prostaglandins F(2 alpha) and E(2) affect cod cardiovascular systems. Prostaglandin F(2 alpha) constricts fish gill arteries, potentially aiding hemostasis, while Prostaglandin E(2) impacts the heart and lowers blood pressure.

Area of Science:

  • Cardiovascular Physiology
  • Fish Biology
  • Eicosanoid Research

Background:

  • Limited understanding of prostaglandin roles in non-mammalian vertebrate cardiovascular systems.
  • Prostaglandins suggested to function in fish hemostasis via filament artery vasoconstriction post-injury.

Purpose of the Study:

  • To investigate the cardiovascular effects of prostaglandins F(2 alpha) (PGF(2 alpha)) and E(2) (PGE(2)) in fish.
  • Focus on the impact of these prostaglandins on branchial circulation.

Main Methods:

  • Intra-arterial injections of PGF(2 alpha) and PGE(2) in cod (Gadus morhua).
  • Dose-response analysis of PGF(2 alpha) (10–400 nmol kg(-1)).
  • In vivo microscopy to observe filament artery response.

Main Results:

  • PGF(2 alpha) caused dose-dependent increases in ventral aortic pressure, decreased cardiac output, and elevated gill vascular resistance.
  • PGF(2 alpha) induced rapid filament artery contraction, suggesting a hemostatic role.
  • PGE(2) primarily affected cardiac function and reduced dorsal aortic blood pressure.

Conclusions:

  • PGF(2 alpha) likely plays a role in hemostatic vasoconstriction in fish gills.
  • PGE(2) exhibits distinct cardiovascular effects, notably impacting cardiac function and systemic blood pressure.

More Related Videos

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Light-sheet Fluorescence Microscopy to Capture 4-Dimensional Images of the Effects of Modulating Shear Stress on the Developing Zebrafish Heart06:51

Light-sheet Fluorescence Microscopy to Capture 4-Dimensional Images of the Effects of Modulating Shear Stress on the Developing Zebrafish Heart

Published on: August 10, 2018

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...